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a  b  s  t  r  a  c  t
Statins  are  inhibitors  of  the  enzyme  3-hydroxy-3-methylglutaryl  coenzyme  A reductase,  the  rate-limiting
step  in  cholesterol  biosynthesis.  Statins  effectively  prevent  and  reduce  the  risk  of  coronary  artery  disease
through  lowering  serum  cholesterol,  and  also exert  anti-thrombotic,  anti-inﬂammatory  and  antioxidant
effects  independently  of changes  in  cholesterol  levels.  On  the  other hand,  clinical  and  experimen-
tal  evidence  suggests  that  abrupt  cessation  of  statin  treatment  (i.e.  statin  withdrawal)  is  associated
with  a deleterious  rebound  phenomenon.  In fact, statin  withdrawal  increases  the  risk  of  thrombotic
vascular  events,  causes  impairment  of endothelium-dependent  relaxation  and  facilitates  experimental
seizures.  However,  evidence  for  statin  withdrawal-induced  detrimental  effects  to  the  brain  parenchyma
is still  lacking.  In  the  present  study  adult  male  Wistar  rats  were  treated  with  atorvastatin  for  seven
days  (10  mg/kg/day)  and  neurochemical  assays  were  performed  in the  cerebral  cortex  30  min  (ator-
vastatin  treatment)  or 24  h (atorvastatin  withdrawal)  after  the  last  atorvastatin  administration.  We
found  that atorvastatin  withdrawal  decreased  levels  of  nitric  oxide  and  mitochondrial  superoxide  dismu-
tase  activity,  whereas  increased  NADPH  oxidase  activity  and  immunoreactivity  for  the protein  nitration
marker  3-nitrotyrosine  in  the  cerebral  cortex.  Catalase,  glutathione-S-transferase and  xanthine  oxidase
activities were  not  altered  by  atorvastatin  treatment  or withdrawal,  as  well  as  protein  carbonyl  and  4-
hydroxy-2-nonenal  immunoreactivity.  Immunoprecipitation  of mitochondrial  SOD  followed  by  analysis
of 3-nitrotyrosine  revealed  increased  levels  of nitrated  mitochondrial  SOD,  suggesting  the  mechanism
underlying  the  atorvastatin  withdrawal-induced  decrease  in  enzyme  activity.  Altogether,  our  results
indicate  the  atorvastatin  withdrawal  elicits  oxidative/nitrosative  damage  in the  rat  cerebral  cortex,  and
that changes  in NADPH  oxidase  activity  and  mitochondrial  superoxide  dismutase  activities  may  underlie
such  harmful  effects.. Introduction
Statins are inhibitors of the enzyme 3-hydroxy-3-methyl-
lutaryl coenzyme A (HMG-CoA) reductase, which catalyzes the
ate-limiting step in cholesterol biosynthesis [1]. As a consequence,
hey effectively prevent and reduce the risk of coronary artery
isease by lowering serum cholesterol levels [1].  Besides their
ction on HMG-CoA reductase, it has been shown that statins
isplay anti-thrombotic [2],  anti-inﬂammatory [2] and antioxidant
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activity [2–5]. Therefore, it has been proposed that statin treatment
would be useful in other conditions than cardiovascular diseases.
In fact, the neuroprotective effects of statins have been reported
in several clinical and experimental conditions, such as traumatic
brain injury [6],  stroke [7],  ischemia [8],  Alzheimer’s disease [5],
excitotoxic aminoacid exposure [9] and seizures [10,11]. However,
compelling clinical and experimental evidence suggests that
abrupt cessation of statin treatment (i.e. statin withdrawal) is
associated with a deleterious rebound phenomenon [10,12–18].
For instance, patients with stable coronary heart disease presented
a threefold increase in thrombotic vascular events after simvas-
tatin treatment was  stopped and continued with relatively lower
Open access under the Elsevier OA license.doses of ﬂuvastatin [12], and statin discontinuation was  associ-
ated with poor outcome and higher mortality after intracerebral
hemorrhage [19]. Another large epidemiologic study showed that
patients who stopped statins on admission for acute myocardial
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nfarction developed more heart failure, ventricular tachycardia, or
eath during hospitalization than patients who were not in statin
reatment [13]. Moreover, cerivastatin or atorvastatin withdrawal
licited oxidative stress and impaired endothelium-dependent
elaxation in mice [14] and rapid loss of statin-mediated protection
n mouse models of cerebral ischemia and thrombus formation
15]. Furthermore, atorvastatin withdrawal facilitated the occur-
ence of pentylenetetrazol-induced seizures, as evidenced by a
ecrease in the latency to clonic and generalized tonic-clonic
eizures [10]. However, evidence for statin withdrawal-induced
armful effects to the brain parenchyma is still lacking.
Considering the widespread use of statins and compelling evi-
ence that statin withdrawal causes important deleterious effects
or which there has been no clear prophylactic strategy [16], it
ecomes important to study the molecular mechanisms underly-
ng such effects. Given the antioxidant activity displayed by statin
reatment and in light of the concept that drug discontinuation
ffects are caused by the biologic adaptation to the drug persisting
fter the drug is cleared from the body [20], we hypothesized that
torvastatin withdrawal elicits oxidative and nitrosative stress in
he rat cerebral cortex. Therefore, the present study aimed to inves-
igate the effects of statin withdrawal on markers of oxidative and
itrosative stress and on the activity of antioxidant and pro-oxidant
nzymes in the rat cerebral cortex, in order to shed some light on the
olecular mechanisms underlying the deleterious effects elicited
y statin withdrawal.
. Material and methods
.1. Animals and reagents
Adult male Wistar rats (250–300 g) were used. Animals were
aintained under controlled light and environment (12:12 h light-
ark cycle, 24 ± 1 ◦C, 55% relative humidity) with free access to
ater and food (SupraTM, Santa Maria, RS, Brazil). All exper-
mental protocols were designed aiming to keep the number
f animals used to a minimum, as well as their suffering.
hese were conducted in accordance with national and inter-
ational legislation (guidelines of Brazilian Council of Animal
xperimentation – CONCEA – and of U.S. Public Health Service’s
olicy on Humane Care and Use of Laboratory Animals – PHS
olicy), and with the approval of the Ethics Committee for Ani-
al  Research of the Federal University of Santa Maria (process
53/2010).
Atorvastatin were extracted from commercially available cap-
ules (Lipitor®). Its identity and purity were checked by nuclear
esonance methods and were >98%. Atorvastatin was  chosen
ecause several studies have shown that its withdrawal wors-
ns outcomes in a number of experimental conditions [10,14,15],
nd because it is the most widely prescribed statin, being used
s the reference group in statin safety studies [21,22]. Primary
ntibodies for mitochondrial SOD and 3-nitrotyrosine (3-NT) were
urchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA, cat-
log numbers sc-30080 and sc-55256, respectively). All the other
eagents were purchased from Thermo Scientiﬁc Pierce Protein
esearch Products (Rockford, IL, USA) or Sigma–Aldrich (St. Louis,
O,  USA).
Animals were treated with atorvastatin (10 mg/kg) or a corre-
ponding volume of vehicle solution (sterile saline solution – 0.9%
aCl) by daily intragastric gavage for 7 days, and in one group treat-
ent was withheld for 24 h before sample collection. Atorvastatin
oses and schedules for administration were chosen based in pre-
ious studies [10,15], and treatment schedules were carried out in
uch a manner that samples from every experimental group were
ollected in a given session.logical Research 71 (2013) 1– 8
2.2. Tissue processing for neurochemical analyses
At the appropriate time according to the schedule described
above, animals were killed by decapitation and had their brain
exposed by the removal of the parietal bone. Cerebral cortices were
rapidly dissected on an inverted ice-cold Petri dish and homoge-
nized in the proper solution for each subsequent neurochemical
analyses, as described below.
2.3. Determination of nitrite plus nitrate content (NOx)
The cerebral cortex was  homogenized 1:5 (m/v) with ZnSO4
(200 mM)  and acetonitrile (96%), centrifuged at 16,000 × g for
30 min at 4 ◦C, and the supernatant was collected for NOx assay
according to the spectrophotometric method based on the Griess
reaction described by Miranda et al. [23]. The resulting pellet was
suspended in NaOH (6 M)  for protein determination.
2.4. Slot blot assays
Levels of protein carbonyls, 3-NT and 4-hydroxy-2-nonenal
protein-adducts (HNE) were determined by slot blot as described
in detail by Joshi et al. [24], except that the cerebral cortex
was homogenized 1:10 (m/v) in 50 mM phosphate-buffered saline
(PBS; pH 7.4) supplemented with a cocktail of protease inhibitors
(1 mM phenylmethanesulfonylﬂuoride, 3 M Aprotinin, 20 M
Leupeptin, 10 M Bestatin, 1 M E-64, 4 M Pepstatin A, 5 mM
EDTA) and was  centrifuged at 13,200 × g at 4 ◦C for 20 min and
supernatants were collected. The speciﬁcity for primary antibodies
against protein carbonyls, 3-NT or HNE was checked by repeat-
ing each experiment with no primary antibody included in the
incubation steps. Under these conditions, no staining was seen on
the blots, suggesting that there was  no non-speciﬁc binding of the
primary antibodies.
2.5. NADPH oxidase activity
NADPH oxidase activity was  measured according to Thannickal
and Fanburg [25], with slight modiﬁcations. Cerebral cortex was
removed and homogenized 1:10 (m/v) in 50 mM PBS (pH 7.4),
then centrifuged at 1000 × g at 4 ◦C for 10 min  and the resulting
supernatant was  used. NADPH oxidase activity was determined by
monitoring NADPH consumption for 90 min  at 37 ◦C in the presence
or absence of the inhibitor diphenyleneiodonium (10 M).
2.6. Xanthine oxidase activity
The cerebral cortex was homogenized 1:10 (m/v) in 50 mM
PBS (pH 7.4) and xanthine oxidase activity was  measured in
whole homogenates according to the spectrophotometric method
described by Zanotto-Filho et al. [26].
2.7. Superoxide dismutase (SOD) activity
For determination of mitochondrial SOD activity, assays were
performed in mitochondrion-enriched fractions, which were
obtained as previously described by Bhattacharya et al. [27], with
some modiﬁcations. Brieﬂy, the cerebral cortex was  rapidly diss-
ected and homogenized in ice-cold isolation buffer A (100 mM
sucrose, 10 mM EDTA, 100 mM Tris–HCl, 46 mM KCl, pH 7.4). The
resulting suspension was  then centrifuged for 3 min  at 2000 × g at
4 ◦C. After centrifugation, the supernatant (S1) was  once more cen-
trifuged for 10 min  at 12,000 × g at 4 ◦C. The resulting supernatant
(S2) was used for determination of cytosolic SOD activity. The pellet
(P2) was  then resuspended in isolation buffer B (100 mM sucrose,
10 mM EDTA, 100 mM  Tris–HCl, 46 mM KCl, and 0.5% bovine serum
macol
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lowing atorvastatin withdrawal (Fig. 3A). On the other hand, no
signiﬁcant differences regarding xanthine oxidase activity were
found [F(2,18) = 0.2629; P > 0.05] (Fig. 3B).C.V. de Oliveira et al. / Phar
lbumin free of fatty acids, pH 7.4) and recentrifuged for 10 min
t 12,000 × g at 4 ◦C. The ﬁnal pellet (P3) was then gently washed
nd resuspended in isolation buffer C (270 mM mannitol, 70 mM
ucrose, 0.02 mM EDTA, 20 mM Tris–HCl, 1 mM K2HPO4, pH 7.4)
nd stored at −20 ◦C. SOD activity was determined in cytosolic
S2) and mitochondrial (P3) fractions as described by Misra and
ridovich [28]. One unit of SOD was deﬁned as the amount of
nzyme required to inhibit the rate of epinephrine autoxidation
y 50% at 37 ◦C.
.8. Catalase (CAT) activity
CAT activity was determined spectrophotometrically as
escribed by Furian et al. [29]. CAT speciﬁc activity was expressed
s ﬁrst-order rate constant, k. Appropriated controls for non-
nzymatic decomposition of hydrogen peroxide were included in
he assays.
.9. Glutathione-S-transferase (GST) activity
Cerebral cortex was homogenized in 50 mM phosphate-
uffered saline and GST activity was assayed spectrophotometri-
ally according to Habig et al. [30].
.10. Western blot assays
The cerebral cortex was rapidly dissected and gently homoge-
ized in ice-cold T-PER tissue protein extraction reagent (Thermo
cientiﬁc), supplemented with Halt Protease Inhibitor Cocktail
Thermo Scientiﬁc). Homogenates were centrifuged at 13,200 × g
t 4 ◦C for 20 min  and supernatants were collected. An aliquot
20 g protein) of the supernatant was mixed with SDS loading
uffer and boiled for 5 min. Proteins were then subjected to a
5% SDS-polyacrylamide gel electrophoresis and transferred to a
VDF membrane. Membranes were blocked with 5% (w/v) bovine
erum albumin (BSA) in Tris-buffered saline, containing 0.04% (v/v)
ween 20 (TBS-T) for 1 h and incubated overnight at 4 ◦C with
 1:5000 dilution of anti-mitochondrial SOD antibodies in TBS-T
ontaining 2.5% BSA. Membranes were washed three times in TBS-
 and incubated for 1 h with biotinylated anti-rabbit secondary
ntibody (1:2500, Sigma Aldrich) in TBS-T containing 2.5% BSA.
embranes were washed three more times and incubated for 1 h
ith a streptavidin peroxidase polymer (1:2500, Sigma Aldrich) in
BS-T containing 2.5% BSA. Blots were developed using 3,3′,5,5′-
etramethylbenzidine, dried, scanned, and quantiﬁed with ImageJ
oftware.
.11. Immunoprecipitation and mitochondrial SOD nitration
nalysis
The cerebral cortex was rapidly dissected and gently homog-
nized as described above for western blot assays, and 500 g of
rotein were subjected to immunoprecipitation and subsequent
etermination of nitrated mitochondrial SOD content by slot blot
ccording to Mamo  et al. [31], with some modiﬁcations. Brieﬂy,
omogenates were precleared with protein A/G-agarose beads
Santa Cruz Biotechnology) for 1 h and incubated overnight with
 1:250 dilution of anti-mitochondrial SOD antibodies or control
gG. Next, samples were incubated for 2 h with protein A/G-agarose
eads and subjected to centrifugation at 1000 × g for 1 min. Pel-
ets were collected, washed three times with protein extraction
eagent, and resuspended in SDS loading buffer. After boiling for
 min, samples were centrifuged at 1000 × g for 1 min  and the
upernatant was used for detection of 3-NT and mitochondrial SOD
y slot blot, as described above.ogical Research 71 (2013) 1– 8 3
2.12. Protein determination
Protein content was measured colorimetrically by the method
of Bradford [32] or by the bicinchoninic acid method using a com-
mercially available kit (Thermo Scientiﬁc Pierce BCA Protein Assay
Kit). Bovine serum albumin (1 mg/mL) was  used as standard.
2.13. Statistical analyses
Data were analyzed by parametric one-way ANOVA and
expressed as mean + standard error of the mean. Post hoc compar-
isons were performed using the Bonferroni test. A probability of
P < 0.05 was  considered signiﬁcant.
3. Results
Since atorvastatin withdrawal has been shown to decrease nitric
oxide levels in endothelial cells [18], our ﬁrst experiment was
aimed to investigate the effect of atorvastatin treatment or with-
drawal NOx levels in the rat cerebral cortex. Nitrite and nitrate are
stable metabolites of nitric oxide, and the sum of nitrite plus nitrate
content (NOx) may  provide information about the nitric oxide lev-
els. Interestingly, statistical analysis (One-way ANOVA followed
by Bonferroni test) revealed a signiﬁcant decrease in NOx  lev-
els following atorvastatin treatment (32.18 ± 8.07%) or withdrawal
(34.65 ± 6.17%) [F(2,31) = 5.248; P < 0.05] (Fig. 1).
Given the above described change in NOx levels and since direct
and indirect antioxidant activity has been reported for atorvastatin
[3–5], we  decided to investigate the effect of atorvastatin treatment
or withdrawal on the levels of selected markers for oxidative or
nitrosative damage. Whereas a signiﬁcant increase (33.4 ± 11.25%)
in 3-NT immunoreactivity was  detected following atorvastatin
withdrawal [F(2,21) = 5.421; P < 0.05] (Fig. 2A), no signiﬁcant differ-
ences in the levels of protein carbonyls [F(2,29) = 0.1357; P > 0.05]
(Fig. 2B) or HNE [F(2,28) = 0.8280; P > 0.05] (Fig. 2C) were found.
Considering that protein nitration (as shown by 3-NT levels)
is typically caused by peroxynitrite, and the main source of this
radical is the reaction between superoxide anion and nitric oxide,
we decided to investigate the effect of atorvastatin treatment or
withdrawal on the NADPH oxidase and xanthine oxidase activities,
two important cellular sources of superoxide anion. Interestingly,
we found a signiﬁcant increase (39.99 ± 9.77%) in NADPH oxidase
activity [F(2,28) = 3.554; P < 0.05] in the rat cerebral cortex fol-Fig. 1. Effect of oral atorvastatin treatment or withdrawal on NOx content in the
rat cerebral cortex. Data are mean + standard error of the mean for n = 10–12 per
group. The asterisk indicates a signiﬁcant difference from the vehicle group (P < 0.05
–  one-way ANOVA followed by the Bonferroni test).
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Superoxide anion can be enzymatically dismutated to a more
table hydrogen peroxide by cytosolic and mitochondrial SOD
ctivities, which are the major ROS detoxiﬁers of the cell. There-
ore, in light of the currently reported increase in NADPH oxidase
ctivity, we decided to determine mitochondrial and cytosolic SOD
ig. 3. Effect of oral atorvastatin treatment or withdrawal on activity of (A) NADPH oxid
rror  of the mean for n = 7–11 per group. The asterisk indicates a signiﬁcant difference fro-nitrotyrosine (3-NT), (B) 4-hydroxy-2-nonenal (HNE) and (C) protein carbonyls in
p. The asterisk indicates a signiﬁcant difference from the vehicle group (P < 0.05 –
activities in the rat cerebral cortex following atorvastatin treat-
ment or withdrawal. Interestingly, atorvastatin withdrawal
decreased mitochondrial SOD activity (by 71.42 ± 18.12%)
[F(2,13) = 10.37; P < 0.05] (Fig. 4A), without altering cytosolic SOD
activity [F(2,12) = 0.4280; P > 0.05] (Fig. 4B). Hydrogen peroxide
ase and (B) xanthine oxidase in the rat cerebral cortex. Data are mean + standard
m the vehicle group (P < 0.05 – one-way ANOVA followed by the Bonferroni test).
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Fig. 4. Effect of oral atorvastatin treatment or withdrawal on activity of (A) mitochondrial SOD and (B) cytosolic SOD, (C) catalase and (D) glutathione-S-transferase in the rat
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NOVA followed by the Bonferroni test).
ay  then be converted into water and oxygen by enzymes
AT and/or through the glutathione system. In this context, we
easured CAT and GST activities in the rat cerebral cortex after
torvastatin treatment or withdrawal. However, no signiﬁcant
ifferences were found regarding CAT [F(2,17) = 0.3044; P > 0.05]
Fig. 4C) or GST [F(2,17) = 0.6098; P > 0.05] (Fig. 4D) activities.
In order to shed some light on the mechanisms underlying the
urrently reported decrease in mitochondrial SOD after atorvas-
atin withdrawal, we measured the expression and level of nitration
f mitochondrial SOD protein, since peroxynitrite-mediated nitra-
ion of selected tyrosine residues in its polypeptide chain greatly
ecreases its catalytic activity [33,34]. Interestingly, atorvastatin
ithdrawal increased mitochondrial SOD immunoreactivity (by
2.2 ± 26.59%) [F(2,15) = 4.145; P < 0.05] (Fig. 5A). In addition, ator-
astatin withdrawal increased the 3-NT/mitochondrial SOD ratio
by 109.8 ± 17.2%) [F(2,11) = 4.039; P < 0.05] (Fig. 5B), indicating
ncreased levels of nitrated mitochondrial SOD.
. Discussion
Statins are cholesterol-lowering agents acting primarily
hrough competitive inhibition of HMG-CoA reductase, but several
xperimental and clinical studies have shown that statins display a
yriad of beneﬁcial effects which appear to be independent fromts cholesterol-lowering action, the so-called pleiotropic effects of
tatins. As such effects appear common to several vascular and
on-vascular diseases, statin treatment has been emerged as a
otential add-on therapy for several conditions [35]. For instance,
ig. 5. Effect of oral atorvastatin treatment or withdrawal on (A) immunoreactivity of m
ortex. Data are mean + standard error of the mean for n = 4–6 per group. The asterisk in
ollowed  by the Bonferroni test).terisk indicates a signiﬁcant difference from the vehicle group (P < 0.05 – one-way
statins alter general immunological responses by altering post-
translational protein prenylation [2,36],  modulate inﬂammation by
inhibiting monocyte-endothelium interactions [2,36],  and increase
production and bioavailability of endothelium-derived nitric oxide
by decreasing Rho GTPase responses [2,36].  In addition, antioxi-
dant actions play a pivotal role in the pleiotropic effects of statin
treatment. In fact, atorvastatin treatment reduced lipoperoxida-
tion, protein oxidation and nitration, and increased GSH levels in
parietal cortex of aged beagles, a well-established preclinical model
of Alzheimer’s disease [5].  Moreover, atorvastatin treatment signif-
icantly increased the antioxidant enzyme biliverdin reductase-A
protein levels, phosphorylation and activity, with a concomitant
decrease in oxidative stress in the parietal cortex of aged beagles
[37]. In the same experimental model of Alzheimer’s disease, ator-
vastatin treatment increased heme oxygenase-1 expression in the
parietal cortex of aged beagles, and a signiﬁcant negative correla-
tion between heme oxygenase-1 protein levels and oxidative stress
parameters has been found [38].
On the other hand, studies in vascular endothelial and smooth
muscle cells and in laboratory animals as well as clinical studies
revealed that discontinuation of statin treatment not only led to a
rapid loss of its vascular protective actions, but was also followed by
a rebound deterioration of vascular health. Importantly, there is no
consensus on how to treat patients undergoing statin withdrawal
or a clear preventive strategy [39]. Therefore, understanding of the
molecular mechanisms underlying the deleterious effects arising
after abrupt cessation of statin therapy are of fundamental impor-
tance. The molecular basis for the adverse cardiovascular effects
itochondrial SOD protein and (B) 3-NT/mitochondrial SOD ratio in the rat cerebral
dicates a signiﬁcant difference from the vehicle group (P < 0.05 – one-way ANOVA
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Fig. 6. A proposed scheme for the effects of atorvastatin withdrawal in the rat
cerebral cortex. Atorvastatin withdrawal increases NADPH oxidase activity (Fig. 3)
and therefore superoxide production. Superoxide anion reacts with nitric oxide,
decreasing nitric oxide levels (Fig. 1) and generating the highly reactive peroxy-
nitrite, which ultimately causes protein nitration (Fig. 2). A possible target of
peroxinitrite is mitochondrial SOD (Fig. 5), which decreased activity (Fig. 4) con-
tributes to maintenance of increased superoxide levels. In addition, decreased
mitochondrial SOD activity may  contribute to NADPH oxidase activation [47],
resulting in a feedforward cycle. l-Arg, l-arginine; l-cit, l-citrulline; NOS, nitric
oxide synthase; NO• , nitric oxide; NADP+, oxidized nicotinamide adenine dinucle-C.V. de Oliveira et al. / Phar
f statin withdrawal has been established [39], but it is not clear
hether such mechanisms for statin withdrawal-induced harmful
ffects can be generalized to other tissues than the cardiovascu-
ar system. In this context, we aimed to investigate the effects of
torvastatin withdrawal on oxidative and nitrosative stress param-
ters in the rat cerebral cortex. Accordingly, in the present study we
howed that abrupt cessation of oral atorvastatin treatment elicited
rotein nitration (as measured by increase 3-NT immunoreactivity)
n the rat cerebral cortex.
Nitric oxide is a little reactive radical produced by nitric oxide
ynthase isozymes (NOS) which display a myriad of physiologi-
al and pathological effects [40]. When nitric oxide interacts with
xygen and superoxide anion, nitrosylation and nitration occur,
espectively. With respect to nitrosylation, nitric oxide interacts
ith oxygen, electron acceptors or metals to produce nitroso-
ium ion, which can subsequently interact with protein thiols
uch as cysteine residues in a reversible manner [41]. Given its
eversibility, protein nitrosylation has been considered a physi-
logical post-translational modiﬁcation which regulates protein
unction in a similar way to phosphorylation [41]. On the other
and, nitric oxide interacts with superoxide to generate the highly
eactive peroxynitrite, leading to tyrosine nitration of proteins [42].
egarding this point, increasing evidence suggest a strong rela-
ionship between protein nitration and the pathophysiology of
everal diseases, including inﬂammatory, neurodegenerative, and
ardiovascular disorders [42]. Protein nitration tyrosine residues
an block protein phosphorylation by interfering with tyrosine
esidues, thus modifying cell signaling pathways [42].
Regarding the source of superoxide for peroxynitrite for-
ation, we found that statin withdrawal increased NADPH
xidase, an important cellular source of superoxide. Interestingly,
hile NADPH oxidase inhibition has been suggested as a major
leiotropic mechanism of statin treatment [2,4,36], statin with-
rawal has been associated with a rebound increase in NADPH
xidase [14]. The mechanisms underlying NADPH oxidase acti-
ation triggered by statin withdrawal are multiple, and include
ncreased plasma membrane targeting of NADPH oxidase catalytic
ubunits through rac1-GTPase and geranylgeranylation [4].  In this
ontext and in agreement with the current literature we found an
ncrease in NADPH oxidase activity in the cerebral cortex of rats
rom statin withdrawal group, indicating that NADPH oxidase could
e an important source of superoxide in this condition.
Interestingly, we a found a decrease in NOx content in the rat
erebral cortex following atorvastatin treatment or withdrawal.
onsidering atorvastatin treatment, there is evidence that statins
ncrease endothelial NOS activity, through augmented enzyme
xpression by lengthening the half-life of its mRNA [36], activation
f protein kinase B/Akt pathway, which in turn activates endothe-
ial NOS by enzyme phosphorylation [36] and restoration of eNOS
ctivity through reduction of caveolin-1 abundance [36]. Since we
ound a decrease in NOx content, it is possible that the statin effect
n endothelial NOS does not occurs in the cerebral cortex. However,
ince nitric oxide production is subjected to direct feedback inhibi-
ion of NOS by nitric oxide [43], decreased nitric oxide levels may  be,
t least in part, explained by this mechanism. One alternative expla-
ation comes from the fact that statins downregulate activity both
euronal NOS and inducible NOS isoforms [44], which are the pre-
ominant NOS isoforms in the brain parenchyma [43]. Moreover,
ecreased NOx content following atorvastatin withdrawal could be
lso be explained by scavenging of nitric oxide by superoxide orig-
nating from NADPH oxidase, resulting in increased peroxynitrite
ormation and protein nitration. Additionally, it should be noted
hat peroxynitrite can decompose to yield nitrate and/or nitrite (i.e.
Ox) by several enzymatic and non-enzymatic mechanisms [45].
or instance, it has been shown that peroxynitrite decomposes at
eutral pH via protonation to peroxynitrous acid to yield nitrateotide phosphate; NADPH, reduced nicotinamide adenine dinucleotide phosphate;
NADPHOX, NADPH oxidase; O2•− , superoxide anion; ONOO•− , peroxynitrite; SOD,
superoxide dismutase.
[45]. In addition, heme proteins, such as hemoglobin and myo-
globin, catalyze the isomerization of peroxynitrite to nitrate, and
enzymes like peroxiredoxins, cyclooxygenase-1 and glutathione
peroxidase may  decompose peroxynitrite to yield nitrite [45]. In
this context, it is also possible that NOx decrease reﬂect at least in
part impairment in one or more pathways of nitrate and/or nitrite
generation from peroxynitrite decomposition.
Importantly, in the present study we  showed that atorvastatin
withdrawal decreases mitochondrial superoxide dismutase. To the
best of our knowledge, this is the ﬁrst report of decreased mito-
chondrial SOD follow statin withdrawal. This enzyme is responsible
for superoxide anion dismutation in water and hydrogen peroxide,
and it is a key scavenger of superoxide in the mitochondrial matrix.
Mitochondrial SOD is vital to life in an oxygen-rich atmosphere,
as demonstrated by several studies in various in vivo models with
reduced mitochondrial SOD expression or enzyme activity [46]. In
addition, altered expression or enzyme activity of mitochondrial
SOD has been linked to many disorders [46], suggesting an impor-
tant role for mitochondrial SOD in disease development. Indeed, the
presently reported decrease in mitochondrial SOD activity adds a
new mechanism underlying the deleterious effects of statin with-
drawal. In this context, our present results are in agreement with
the emerging concept of the existence of a cross talk between
mitochondria and cytosolic NADPH oxidases [47] (Fig. 6). In fact,
it has been demonstrated that increased levels of mitochondrial
superoxide activate cytosolic NADPH oxidases, increasing superox-
ide production in the cytoplasm [48]. Since NADPH oxidase-derived
superoxide stimulate protein kinase C within the mitochondrial
matrix [49] and leads to depolarization of mitochondrial membrane
potential followed by mitochondrial ROS formation and respiratory
chain dysfunction [49], such interplay constitutes a feedforward
cycle in which the NADPH oxidases increase mitochondrial reactive
species, which further activate the cytoplasmic NADPH oxidases
and increase cellular superoxide production, triggering mitochon-
drial impairment and diminishing nitric oxide bioavailability [47].
Regarding the mechanism for decreased mitochondrial SOD
activity, it has been demonstrated that this enzyme is a target for
peroxynitrite-mediated nitration, which ultimately decreases its
macol
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ctivity [33,34].  In fact, mitochondrial SOD appears to be hyper-
ensitive toward nitration, accounting for as much as 20% of total
rotein nitration under conditions of oxidative stress [50]. In light
f our present results, it is plausible to propose that decreased mito-
hondrial SOD activity elicited by atorvastatin withdrawal may  be
 result of nitration of selected tyrosine residues in its polypep-
ide chain, since abrupt discontinuation of atorvastatin treatment
ncreased 3-NT/mitochondrial SOD ratio, indicating that levels of
itrated mitochondrial SOD are increased in the rat cerebral cor-
ex following atorvastatin withdrawal. Interestingly, we found that
itochondrial SOD immunoreactivity was increased after atorvas-
atin withdrawal, suggesting increased expression of this enzyme
n the rat cerebral cortex. Considering the decrease in mitochon-
rial SOD activity following atorvastatin withdrawal, an increase
n protein levels could represent a cellular attempt to compensate
ecreased enzyme activity, which ultimately revealed ineffective
ossibly because nitration of key tyrosine residues in mitochondrial
OD following atorvastatin withdrawal.
. Conclusion
In summary, in the present study we showed that atorvastatin
ithdrawal elicits oxidative/nitrosative damage in the rat cere-
ral cortex and that this effect may  be mediated by increased
ADPH oxidase activity and decreased mitochondrial SOD activ-
ty. A proposed scheme of our present results is shown in Fig. 6.
lthough additional studies are necessary to evaluate the clinical
mplications of our ﬁndings, it is possible that antioxidant strate-
ies targeting NADPH oxidase or mitochondrial SOD activities may
onstitute potential targets for prophylaxis and/or treatment of the
eleterious effects of statin withdrawal to the brain.
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